The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Exondys 51 Market Through 2030?

The historical development was influenced by the scarcity of curative therapies for DMD, a traditional focus on supportive interventions, nascent antisense research efforts, motivators for rare disease medications, and the preliminary regulatory endorsements.

Anticipated growth in the forecast period is linked to breakthroughs in molecular genetics, the expansion of individualized neuromuscular care, a rise in newborn screening programs, increased financial backing for dmd research, and the emergence of specialized neurology centers. Prominent trends for this period include the proliferation of exon skipping therapies, a broadening of targeted dmd treatments, increased uptake of genetic-based medicines, a concentrated effort on retarding disease progression, and enhanced long-term therapy management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20071&type=smp

Which Growth Drivers Are Expected To Support The Exondys 51 Market Forward?

The Exondys 51 market is projected to experience growth driven by the increasing prevalence of genetic disorders. Genetic disorders are medical conditions resulting from anomalies or mutations in an individual’s DNA or genetic makeup. The rising occurrence of genetic disorders can be attributed to several factors, including developments in medical technology, demographic shifts, and improvements in diagnostic methods and public awareness. Exondys 51 (eteplirsen) treats genetic disorders by facilitating exon 51 skipping in the dystrophin gene, allowing for the creation of a functional, though truncated, dystrophin protein to slow down muscle degeneration. For instance, in July 2024, the National Health Service, a UK-based government department, indicated that roughly 70,000 individuals in the UK are affected by muscular dystrophy (MD) or related conditions, with Duchenne MD being the most common variant. Each year, approximately 100 boys are diagnosed with Duchenne MD, and about 2,500 people in the UK live with this condition at any given time. Therefore, the increasing burden of genetic disorders is a significant factor driving the expansion of the Exondys 51 market.

What Segment Types Are Included In The Exondys 51 Market Analysis?

The exondys 51 market covered in this report is segmented –

1) By Clinical Indication: Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Other Multiple Sclerosis Forms

2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies

3) By Application: Subcutaneous Injection, Long-Term Disease Management, Prophylactic Use

Which Trends Are Influencing The Expansion Of The Exondys 51 Market?

Major companies within the exondys 51 market are increasingly prioritizing enhanced safety and refined patient selection, such as through updates to prescribing information for ELEVIDYS to mitigate liver-related risks and ensure appropriate patient eligibility. ELEVIDYS refers to Sarepta Therapeutics’ AAV-based micro-dystrophin gene therapy (delandistrogene moxeparvovec) designed to restore dystrophin expression in patients with Duchenne muscular dystrophy (DMD). As an illustration, in November 2025, the U.S. FDA, a US-based federal agency, approved a revised label for ELEVIDYS, which incorporated a boxed warning for acute serious liver injury and acute liver failure, and restricted its use to ambulatory patients aged four years and older. This update mandates weekly liver-function testing for the initial three months post-infusion, requires corticosteroid pre- and post-dosing, and recommends that patients remain near a qualified healthcare facility for at least two months, all aimed at improving safety monitoring and patient outcomes.

Which Organizations Are Involved In The Exondys 51 Market?

Major companies operating in the exondys 51 market are Sarepta Therapeutics

Access The Complete Exondys 51 Market Report:

https://www.thebusinessresearchcompany.com/report/exondys-51-global-market-report

Which Region Stands As The Largest Contributor To The Exondys 51 Market?

North America was the largest region in the exondys 51 market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the exondys 51 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.